WO2026082960A1 - Inhibiteurs d'alk5 à base de 1,5-naphtyridine et de quinoléine - Google Patents

Inhibiteurs d'alk5 à base de 1,5-naphtyridine et de quinoléine

Info

Publication number
WO2026082960A1
WO2026082960A1 PCT/EP2025/080074 EP2025080074W WO2026082960A1 WO 2026082960 A1 WO2026082960 A1 WO 2026082960A1 EP 2025080074 W EP2025080074 W EP 2025080074W WO 2026082960 A1 WO2026082960 A1 WO 2026082960A1
Authority
WO
WIPO (PCT)
Prior art keywords
chloro
fluorophenyl
carboxylate
pyrazol
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2025/080074
Other languages
English (en)
Inventor
Begoña PAMPÍN CASAL
Rosalino BALO BECERRA
Borja CENDÓN MARIÑO
Gordon Saxty
Reginald Christophe Xavier Brys
Gert Jules Hector De Wilde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agomab Therapeutics NV
Original Assignee
Agomab Therapeutics NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agomab Therapeutics NV filed Critical Agomab Therapeutics NV
Publication of WO2026082960A1 publication Critical patent/WO2026082960A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés de formule (I) qui sont des inhibiteurs de la kinase 5 de type récepteur à l'activine (ALK5) et des utilisations associées.
PCT/EP2025/080074 2024-10-18 2025-10-17 Inhibiteurs d'alk5 à base de 1,5-naphtyridine et de quinoléine Pending WO2026082960A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP24383143 2024-10-18
EP24383143.5 2024-10-18

Publications (1)

Publication Number Publication Date
WO2026082960A1 true WO2026082960A1 (fr) 2026-04-23

Family

ID=93291896

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2025/080074 Pending WO2026082960A1 (fr) 2024-10-18 2025-10-17 Inhibiteurs d'alk5 à base de 1,5-naphtyridine et de quinoléine

Country Status (1)

Country Link
WO (1) WO2026082960A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020123453A2 (fr) 2018-12-11 2020-06-18 Theravance Biopharma R&D Ip, Llc Inhibiteurs d'alk5
WO2021102468A1 (fr) 2019-11-22 2021-05-27 Theravance Biopharma R&D Ip, Llc 1,5-naphtyridines ou quinoléines substituées en tant qu'inhibiteurs d'alk5
WO2021105317A1 (fr) 2019-11-28 2021-06-03 Origo Biopharma, S.L. Dérivés de benzylamide utilisés en tant qu'inhibiteurs du récepteur i/alk5 du facteur de croissance transformant bêta
WO2022006340A1 (fr) * 2020-07-01 2022-01-06 Silverback Therapeutics, Inc. Inhibiteurs d'alk5, conjugués et leurs utilisations
WO2022069509A1 (fr) 2020-09-30 2022-04-07 Origo Biopharma, S.L. Dérivés de 2-(3-pyridin-2-yl-4-quinoléin-4-yl-pyrazol-1-yl)-acétamide utilisés en tant qu'inhibiteurs du récepteur i/alk5 du facteur de croissance transformant bêta

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020123453A2 (fr) 2018-12-11 2020-06-18 Theravance Biopharma R&D Ip, Llc Inhibiteurs d'alk5
WO2021102468A1 (fr) 2019-11-22 2021-05-27 Theravance Biopharma R&D Ip, Llc 1,5-naphtyridines ou quinoléines substituées en tant qu'inhibiteurs d'alk5
WO2021105317A1 (fr) 2019-11-28 2021-06-03 Origo Biopharma, S.L. Dérivés de benzylamide utilisés en tant qu'inhibiteurs du récepteur i/alk5 du facteur de croissance transformant bêta
WO2022006340A1 (fr) * 2020-07-01 2022-01-06 Silverback Therapeutics, Inc. Inhibiteurs d'alk5, conjugués et leurs utilisations
WO2022069509A1 (fr) 2020-09-30 2022-04-07 Origo Biopharma, S.L. Dérivés de 2-(3-pyridin-2-yl-4-quinoléin-4-yl-pyrazol-1-yl)-acétamide utilisés en tant qu'inhibiteurs du récepteur i/alk5 du facteur de croissance transformant bêta

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY
AKHURST, R. J. ET AL.: "Targeting the TGFβ signalling pathway in disease", NATURE REVIEWS, vol. 11, no. 10, 2012, pages 790 - 811
ASCHNER, Y. ET AL.: ", Transforming Growth Factor-β: Master Regulator of the Respiratory System in Health and Disease", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, vol. 54, no. 5, 2016, pages 647 - 655
BIERIE, B. ET AL.: ", TGF-β: the molecular Jekyll and Hyde of cancer", NATURE REVIEWS CANCER, vol. 6, 2006, pages 506 - 520
BIERNACKA, A. ET AL.: ", TGF-β signalling in fibrosis", GROWTH FACTORS, vol. 29, no. 5, 2011, pages 196 - 202
HELDIN, C. H. ET AL.: ", Signalling Receptors for TGF-b Family Members", COLD SPRING HARB PERSPECT BIOL, vol. 8, no. 8, 2016, pages 1 - 33
HOWELL, J. E. ET AL.: ", TGF-β: Its Role in Asthma and Therapeutic Potential", CURRENT DRUG TARGETS, vol. 7, no. 5, 2006, pages 547 - 565
LI, S. W. ET AL.: ", SARS coronavirus papain-like protease induces Egr-1-dependent up-regulation of TGF-β1 via ROS/p38 MAPK/STAT3 pathway", SCI REP., vol. 6, 2016, pages 25754
MURGO, A. ET AL.: ", Harnessing the translational power of bleomycin model: new insights to guide drug discovery for idiopathic pulmonary fibrosis.", FRONT PHARMACOL., vol. 14, 2023, pages 1303646
SAITO, A. ET AL.: ", TGF-β Signaling in Lung Health and Disease", INT. J. MOL. SCI.,, vol. 19, no. 8, 2018, pages 2460
WANG, J. ET AL.: ", Targeting Transforming Growth Factor-b Signalling in Primary Open-Angle Glaucoma", J GLAUCOMA, vol. 26, no. 4, 2017, pages 390 - 395
XIA, Y. C. ET AL.: ", Glucocorticoid Insensitivity in Virally Infected Airway Epithelial Cells Is Dependent on Transforming Growth Factor-β Activity", PLOS PATHOG, vol. 13, no. 1, 2017, pages 1006138

Similar Documents

Publication Publication Date Title
AU2012312305B2 (en) Acyclic cyanoethylpyrazoles as janus kinase inhibitors
TWI618703B (zh) 激酶抑制劑
EP3423445B1 (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de la fibrose
US10590077B2 (en) TRPV4 antagonists
US20180338980A1 (en) Aromatic sulfonamide derivatives
KR20160018567A (ko) 키나아제 억제제
KR102226098B1 (ko) 5-[2-(피리딘-2-일아미노)-1,3-티아졸-5-일]-2,3-디하이드로-1h-이소인돌-1-온 유도체 및 포스파티딜이노시톨 3-키나제 델타 및 감마의 이중 억제제로서의 이의 용도
CN115785068A (zh) Kif18a抑制剂
JP2020503288A (ja) 選択的ヤヌスキナーゼ阻害剤としてのアミノピラゾール類
TW201315727A (zh) 尿嘧啶衍生物及其醫藥用途
KR20220003537A (ko) Jak1 선택적 키나제 억제제
CN105189497A (zh) 作为janus激酶抑制剂的n-(2-氰基杂环基)吡唑并吡啶酮
JP2021529819A (ja) Ｒｈｏキナーゼ阻害剤としてのチロシンアミド誘導体
CN116354992A (zh) 一类pde4抑制剂及其在药物中的应用
WO2026082960A1 (fr) Inhibiteurs d'alk5 à base de 1,5-naphtyridine et de quinoléine
WO2026082968A1 (fr) Nouveaux composés
KR20230141787A (ko) 피라졸아미드 유도체
EP4263547B1 (fr) Dérivés de dihydrofuropyridine en tant qu'inhibiteurs de rho-kinase
JP7618898B1 (ja) ヒト呼吸器合胞体ウイルス及びメタニューモウイルスの阻害薬
KR20210149077A (ko) 포스포이노시타이드 3-키나아제 억제제로서 아이소크로멘 유도체
CN116354862A (zh) 取代的氮杂环类化合物及其在药物中的应用
WO2022128848A1 (fr) Dérivés de dihydrofuropyridine en tant qu'inhibiteurs de la rho-kinase
HK40062362A (en) Bicyclic pyrrolotriazolr ketone compounds and methods of use thereof
HK1139058B (en) Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group
HK1139058A1 (en) Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group